PUNE, India, May 3, 2019 /PRNewswire/ -- Cardiovascular Diseases Market research reports will assist you to gain an understanding of the cardiovascular clinical and commercial landscape and identify leading products and key unmet needs. Visualize the composition of the Cardiovascular Diseases Market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players. Our reports will help you to identify commercial opportunities in the cardiovascular deals landscape by analyzing trends in licensing and co-development deals.

ReportsnReports offers a Discount on Cardiovascular Diseases Market Research Reports (Bundle of 3 Reports till 31 May 2019).

Access Complete Bundle- 3 Reports of Cardiovascular Diseases Market Research Reports at https://www.reportsnreports.com/reports/2178318-cardiovascular-diseases-market-research-reports-bundle-offer-3-reports.html

1. Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis

This report provides analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years, and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs that have not yet been involved in a licensing or co-development deal appear to be particularly promising?

Scope:

- With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?

- There are 320 first-in-class products in the CVD market that act on a novel molecular target thatis not present in an approved product across any indication in the pharmaceutical industry. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?

- Analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years, and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs that have not yet been involved in a licensing or co-development deal appear to be particularly promising?

For More Details on this Research Report at https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=2178318 

2. Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

The CVD market landscape is forecast to undergo a period of substantial change following key approvals, patent expiries and acquisitions. Which of the leading companies will have the highest market share by 2023? What strategies have these companies adopted to achieve market growth?

Scope:

- With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?

- The clinical trials process for CVD drugs is complex. What is the risk of a CVD drug failing to reach the market? What is the risk of a drug failing at a specific Phase?

- The CVD market landscape is forecast to undergo a period of substantial change following key approvals, patent expiries and acquisitions. Which of the leading companies will have the highest market share by 2023? What strategies have these companies adopted to achieve market growth?

- There has been a moderately high level of deal activity in recent years. How do deal frequency and value compare between target families and molecule types?

Cardiovascular Diseases Market Research Reports Bundle Offer - 3 Reports is available at US $ 7993 for Single User License till 31 May 2019. To Order a Report at https://www.reportsnreports.com/purchase.aspx?name=2178318 

3. Cardiovascular Disorders Drug Development Pipeline Review, 2017

This report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. 

Scope:

• Which companies are the most active within the pipeline for CVD?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in this disease area?

About Us: 

ReportsnReports.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.

Contact:  

Ganesh Pardeshi
Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India
+1-888-391-5441
sales@reportsandreports.com

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/ 
LinkedIn: https://www.linkedin.com/company/reportsnreports 
Twitter: https://twitter.com/marketsreports 
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports